Startup based in the United States, most recent round Series A, 2 tracked investors.
XXII is a company headquartered in the United States. Its most recent tracked round is Series A. Brouky records 2 investors associated with the company.
XXII, also known as 22nd Century Group, is a plant biotechnology company focused on tobacco harm reduction and cannabis research. They develop technologies to reduce nicotine in tobacco and modify cannabinoid profiles in cannabis.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.